Effective from April, comprehensive changes to the regulations governing the substitution of biologic medicines, specifically biosimilars, will be implemented in Germany. The Joint Federal Committee (G-BA) has clarified the criteria for the mandatory substitution of these complex drugs, a move that is expected to have significant implications for pharmacies, healthcare providers, and patients.

Under the revised framework, pharmacies are now required to substitute prescribed biologic medications with approved biosimilars when certain conditions are met. This policy aims to harmonize the rules for biologic drug interchange with those that have long applied to generic medicines, introducing greater consistency and cost-efficiency to the healthcare system.

Key Provisions of the New Substitution Policy

The updated regulations dictate that, in the presence of a rebate contract for a particular biologic or biosimilar, pharmacies must prioritize dispensing the product specified in the agreement. If no such contract exists, pharmacists are obligated to provide one of the four most cost-effective medicines available for the prescribed therapy.

However, strict criteria must be met before substitution is allowed. The dispensed biosimilar must be authorized for at least one of the same therapeutic indications as the originally prescribed product and must be approved for the same methods of administration. Furthermore, equivalence must be ensured in terms of dosage strength and packaging size, and the pharmaceutical form--such as pre-filled syringe, pen device, or cartridge--must be identical or deemed interchangeable.

Substitution is permitted not only between a reference biologic and its biosimilars but also among biosimilars that reference the same original biologic. This is intended to ensure therapeutic continuity and patient safety while supporting the objectives of the healthcare system to manage costs more effectively.

Clarification of Key Definitions

The framework agreement, which will be updated to reflect these changes, offers precise definitions to guide stakeholders. A reference medicine is defined as a product with its own marketing authorization, serving as the benchmark for subsequent biosimilars during regulatory approval. For imported products classified as bioidenticals, identical rules apply as for generics, ensuring a level playing field across the sector. In the context of biologics, a reference medicine typically refers to a biotechnologically produced drug that forms the basis for the approval of biosimilars or bioidenticals.

Industry Perspectives and Implications

While these measures are designed to generate substantial savings for statutory health insurers, some industry representatives have expressed concerns. They warn that the expansion of mandatory substitution could create downward price pressures, potentially affecting the competitiveness of German manufacturers and threatening the country's leadership in the production of advanced biologic medicines.

Health authorities, however, maintain that the new regulations are both safe and necessary. By establishing robust criteria for substitution, the policy balances cost containment with the need to maintain high therapeutic standards and patient protection.

Next Steps for Pharmacies and Healthcare Providers

Pharmacies will need to carefully review prescriptions for biologics, ensuring all substitution conditions are met before dispensing an alternative. Where applicable, rebate contracts will take precedence, and pharmacists must remain vigilant regarding product equivalence in terms of indication, administration method, strength, and packaging.

These regulatory adjustments represent a significant step toward the broader integration of biosimilars into routine clinical practice and underscore Germany's ongoing commitment to optimizing healthcare delivery through evidence-based policy reforms.